Continuous amnioinfusion via a subcutaneously implanted port system with PPROM and anhydramnios < 28+0 weeks of gestation: an international prospective randomized trial

Mid-trimester PPROM occurs in 1% of pregnancies leading to a high neonatal mortality and morbidity rate, causing extreme preterm birth combined with the “fetal inflammatory response syndrome” (FIRS), thus inducing lung hypoplasia. Purpose: The evaluation of continuous amnioinfusion therapy joining a 7 day lasting antibiotic treatment with PPROM and oligo-/anhydramnios (SDP = single deepest pocket < 2 cm) between 22+0 until 27+6 weeks of gestation compared to the antibiotic therapy appropriate to national guidelines is the objective of this prospective randomized trial. Material and methods: 48 patients will part…